ROIVANT SCIENCES LTD (ROIV) is drawing unusual attention today. Our newswire has captured 1 story on ROIV across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
ROIV stock surged 18.75% to $41.48 on Monday, reaching a 52-week high, driven by positive Phase 2 trial results for its experimental drug, mosliciguat, which met endpoints in treating pulmonary hypertension. The drug’s success in the PHocus study sparked strong investor interest, propelling the stock to its highest level since its 52-week low of $12.53. The move also coincided with the company’s presentation at the Wells Fargo Healthcare Conference, which added to the momentum.
Roivant Sciences announced that mosliciguat, its investigational therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD), met its primary and secondary endpoints in the Phase 2 PHocus trial. The drug demonstrated significant improvements in functional capacity and pulmonary vascular resistance, which are key indicators of treatment effectiveness. The results were disclosed in a press release and discussed in detail during the company’s presentation at the Wells Fargo 21st Annual Healthcare Conference on September 8. The positive data led to a sharp rise in investor sentiment, with the stock climbing nearly 19% in a single session.
In addition to the trial results, two separate price targets were raised for ROIV. H.C. Wainwright increased its price target to $47 from $41, while Jefferies raised its target to $52. These upgrades signaled growing confidence in the stock’s potential, even as the company remains unprofitable with a trailing twelve-month revenue decline of 67.6% and an EPS of -0.49.
The stock has risen 13.2% over the past eight sessions, moving from $36.76 to $41.62. Options activity also showed a strong skew toward calls, with $8.2 million in call premiums compared to just $71,000 in puts. The largest single print in the last 36 hours was $4.4 million, indicating significant institutional or large retail interest. Meanwhile, insider transactions over the past 90 days have totaled $247.5 million in sales, with no insider buys recorded. The stock also printed its 18th 52-week high on September 8, reinforcing its recent strength.
The stock is currently trading near its 52-week high, and no near-term earnings date is listed. Investors will likely monitor coverage breadth and any further developments in the mosliciguat pipeline, as well as the response from the broader market to the recent price target upgrades.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Roivant Sciences outlook: LISRAYA approval strengthens revenue, while brepocitinib and mosliciguat could expand immunology/pulmonary franchises. Click for more on ROIV stock.
ROIVANT SCIENCES LTD (ROIV) is drawing unusual attention today. Our newswire has captured 1 story on ROIV across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ROIV coverage reads 58/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on ROIV: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ROIV move explainers: 2026-09-09 · 2026-09-08 · 2026-08-28